To clarify some characteristics of phosphatidylinositol glycanclass A gene (PIG-A) mutations in aplastic anemia (AA) and myelodysplastic syndrome (MDS) patients compared with those in paroxysmal nocturnal hemoglobinuria (PNH) patients, we investigated PIG-A mutations in CD59 À granulocytes and CD48
Introduction
Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired clonal hematological disorder affecting all hematopoietic lineages, which lack glycosylphosphatidylinositol (GPI)-anchored membrane proteins owing to mutations in the phosphatidylinositol glycan-class A (PIG-A) gene. 1 The PIG-A gene consists of six exons and five introns and is involved in the first step of GPI-anchor biosynthesis; the transfer of N-acetylglucosamine to phosphatidylinositol. 2 All the PNH patients reported previously, in whom the PIG-A gene was examined, had abnormal PIG-A mRNA and/or genomic DNA in various cell lineages. 3 Therefore, PNH clones can be defined as GPIdeficient cell populations having PIG-A mutations. PIG-A gene analysis is very useful for understanding the pathophysiology of PNH, such as the clonality of PNH clones.
Aplastic anemia (AA), myelodysplastic syndrome (MDS), and PNH are included in the bone marrow failure syndromes, which are manifested by aplastic or hypoplastic bone marrow and clonal hematopoiesis. 4 Recently, several researchers reported that 15-88.6% of untreated and/or treated AA patients have GPIdeficient cells [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] as do 10-23% of MDS patients. 12, [15] [16] [17] The proportions of GPI-deficient cells in AA and MDS patients varied greatly (0.003-99%) and were usually lower than those in PNH patients. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] In addition, PIG-A mutations have partially been reported in patients with AA, 11, 18 AA/PNH, 3, 19 and MDS. 15, 17 However, it could not be ruled out that these AA and MDS patients analyzed for PIG-A gene abnormality are actually PNH, because the AA and MDS patients had 2.4-28.5% and 1.19-22% of GPI-negative erythrocytes, respectively. Therefore, some characteristics of PNH clones in AA and MDS patients with less GPI-negative erythrocytes, including their clonality, are not clear.
To clarify whether PIG-A mutations in AA and MDS patients are identical to those reported previously in PNH patients and whether or not clonality of PNH clones in AA and MDS patients is different from that in PNH patients, we investigated the expression of CD59 on granulocytes and of CD48 on monocytes by using flow cytometry and the nucleotide sequences of PIG-A gene-coding regions in the GPI-deficient granulocytes and/or monocytes from seven AA and 8 MDS Japanese patients with below 1% of GPI-negative erythrocytes.
Materials and methods

Patients and controls
After obtaining informed consent and approval from the institutional Human Research Committee, peripheral blood samples were taken from these patients: seven AA and eight MDS Japanese patients during the period from November 2001 to February 2003; and from six AA patients, except for Case 6; three MDS patients, including Cases 10, 11, and 14, and 11 Japanese patients with PNH during the period from May to August 2005. Unfortunately, Case 13 did not allow sorting of CD48 À monocytes during the former period and aspiration of peripheral blood by venipuncture during the latter period. Cases 6, 8, 9, and 15 died of sepsis following phlegmonitis, acute pneumonia, pneumonitis, and disseminated intravascular coagulation following sepsis, respectively, and Case 12 was transferred to another hospital outside the prefecture during the period from March 2003 to May 2005. The diagnosis and grading of the severity of AA were based on the criteria of the International Agranulocytosis and Aplastic Anemia Study Group 20 and that of Frickhofen et al., 21 respectively. Severe AA was established when at least two of the following criteria were met: absolute numbers of reticulocytes, neutrophils, or platelets less than 20 Â 10 9 /l, 0.5 Â 10 9 /l, or 20 Â 10 9 /l, respectively. Very severe AA was established if it met the criteria for severe AA and the neutrophil count was below 0.2 Â 10 9 /l. Nonsevere AA did not meet the criteria for severe or very severe disease. The diagnosis and phenotype of MDS were determined from peripheral blood cell and bone marrow cell cytomorphology and chromosomal findings after excluding other disorders presenting with pancytopenia according to the French-American-British (FAB) criteria 22 at the time of examination. Chromosomal analyses indicated that Cases 8, 10, and 12 had abnormal karyotypes of 45, XY, À7 (20/20 cells), 45, XX, der (14;21)(q10;q10)(14/20 cells), and 47, XY, þ 8 (20/20 cells), respectively, and that the other patients had normal karyotypes. The diagnosis of PNH was made on the basis of the history, clinical and laboratory findings, and the results of CD59 expression on erythrocytes as determined by flow cytometry. A patient with over 1% of CD59
À erythrocytes was judged to have PNH erythrocytes. 23, 24 The clinical, hematologic, and laboratory findings at diagnosis and/or at the time of examination in each patient are shown in Table 1 . During the study period described above, the diagnosis of Case 5 changed from AA to PNH (Case 26)(AA-PNH syndrome). 25 As controls, after informed consent peripheral blood samples were obtained from 20 age-matched healthy individuals (mean age, 47.8 years; range, 22-56 years) for analysis of CD59 expression on granulocytes and CD48 expression on monocytes by using flow cytometry, from five of 20 healthy volunteers for sequence analysis of the PIG-A gene in CD59 À granulocytes and CD48 À monocytes, and from one of 20 healthy individuals for the analysis in CD59 þ granulocytes and CD48 þ monocytes.
Monoclonal antibodies
Mouse monoclonal antibodies to CD59 (3E1; IgG1), 26 CD59 labeled with fluorescein isothiocyanate (H19; IgG2a, k; BD PharMingen, San Diego, CA, USA), and CD48 labeled with fluorescein isothiocyanate (J4-57; IgG1; Immunotech, Marseille, France) were used for one-color flow cytometry of erythrocytes, granulocytes, and monocytes, respectively. Irrelevant monoclonal antibodies of the same subclasses were used as negative controls. 23, 27 Preparation of peripheral blood granulocytes and mononuclear cells
Granulocytes and monocytes were prepared from peripheral blood as described previously. 28, 29 Briefly, peripheral blood samples were collected into syringes containing acid-citratedextrose solution A (Terumo, Tokyo, Japan). The samples were mixed with 6% dextran in a ratio of 3:1, left for 60 min at room temperature, and then subjected to density gradient centrifugation using Lymphoprep (Nycomed Pharma, Oslo, Norway). Granulocytes and mononuclear cells were recovered from the pellet and interface, respectively. Contaminating erythrocytes were removed by hypotonic lysis and the cells were then washed twice in phosphate-buffered saline containing 1% bovine serum albumin (PBS-BSA). The granulocytes and mononuclear cells were suspended at 2 Â 10 7 cells/ml in PBS-BSA and used for immunofluorescent staining and flow cytometry.
Immunofluorescent staining, flow cytometry, and cell sorting One-color flow cytometry of erythrocytes was performed as described previously. 23, 27 One-color flow cytometric analyses of granulocytes for CD59 and of monocytes for CD48 were performed as described previously, 28 
Polymerase chain reaction and nucleotide sequence analysis of genomic DNA
The oligonucleotide primers used for polymerase chain reaction (PCR) amplification were designed according to the PIG-A cDNA and PIG-A genomic DNA sequence, as previously described.
2,28-30 Genomic DNA was obtained from the sorted cells (1 Â 10 4 cells) using InstaGene Matrix (Bio-Rad Laboratories, Hercules, CA, USA). Genomic PIG-A DNA was amplified by PCR using AmpliTaq Gold polymerase (PE Applied Biosystems, Foster City, CA, USA). PCRs consisted of denaturing at 951C for 9 min, 45 cycles of 941C for 30 s, 551C for 1 min, and 721C for 2 min, and extension at 721C for 7 min. The amplified products were subcloned into pCR4-TOPO vectors (Invitrogen Corporation, Carlsbad, CA, USA) with a TOPO TA cloning kit (Invitrogen). Twenty or 40 bacterial clones of genomic PIG-A DNA were analyzed by nucleotide sequencing using a BigDye Terminator Cycle Sequencing Ready Reaction kit (PE Applied Biosystems) and Model 3100 Genetic Analyzer (PE Applied Biosystems). To exclude PCR errors, only PIG-A gene mutations identified in at least two independent bacterial clones with two independent PCR reactions are listed.
28,29
Statistical analysis
All statistical analyses were performed by the w 2 test or the Fisher's exact probability test, as appropriate. A value of Po0.05 was considered significant.
Results
Expression of GPI-anchored proteins by erythrocytes, granulocytes, and monocytes from AA, MDS, and PNH patients
Erythrocytes from all the AA and MDS patients and healthy volunteers or from PNH patients consisted of a single CD59 Neg. refers to negative populations by one-color flow cytometric analyses of erythrocytes and granulocytes using CD59 monoclonal antibody and of monocytes using CD48 monoclonal antibody. c Neg. in these cases includes various proportions of intermediate and negative populations of CD59 expression. Parentheses indicate grading of the severity of AA and hematologic data at diagnosis in AA patients. Abbreviations: bp, base pair; A, adenine; G, guanine; T, thymine; C, cytosine; Val, valine; Met, methionine; Ser, serine; Pro, proline; Phe, phenylalanine; Leu, leucine; Thr, threonine; Ala, alanine; Arg, arginine; Asp, asparaginic acid; Gly, glycine; Ile, isoleucine; Asn, asparagine; His, histidine; and Glu, glutamic acid. a Indicates the proportions of the mutated bacterial clones versus total bacterial clones examined in each cell lineage. 
PIG-A gene analyses for GPI-deficient granulocytes and/or monocytes from AA and MDS patients and healthy individuals
We determined the nucleotide sequences of the PIG-A coding region of CD59 À granulocytes from five (at the first examination) or five (at the second examination) AA and six or three MDS patients and five healthy individuals, of CD48 À monocytes from four or five AA and four or three MDS patients and five healthy individuals, and of CD59 þ granulocytes and CD48 þ monocytes from a healthy volunteer. One or 2-8 kinds of PIG-A mutations were found in GPI-negative granulocytes and monocytes from each AA and MDS patient (Tables 2 or 3 , respectively). The proportions of PIG-A mutations in GPI-negative cells from the patients ranged from 5 to 95% or 5 to 65% (Tables  2 or 3 , respectively). In contrast, no PIG-A mutations were found in 20 bacterial clones derived from GPI-positive cells from a healthy volunteer, but one to six kinds of PIG-A mutations in them derived from CD59 À granulocytes and/or CD48 À monocytes from three of five healthy individuals ( Table 3) .
The frequencies of base substitution, deletion, insertion, and complex base change in the PIG-A gene were 25 (51.0%), eight Abbreviations: bp, base pair; A, adenine; G, guanine; T, thymine; C, cytosine; Met, methionine; Val, valine; Ile, isoleucine; Ala, alanine; Thr, threonine; Asn, asparagine; Ser, serine; Gly, glycine; Glu, glutamic acid; Lys, lysine; Arg, arginine; Tyr, tyrosine; Cys, cysteine; His, histidine; Gln, glutamine; Leu, leucine; Pro, proline; Asp, asparaginic acid; Trp, tryptophan; HV, healthy volunteer; and ND, not detected.
a Indicates the proportions of the mutated bacterial clones versus total bacterial clones examined in each cell lineage.
Features of PIG-A mutations in AA and MDS M Okamoto et al 631 (16.3%), 16 (32.6%), and zero (0%), respectively, in AA patients and 21 (63.6%), seven (21.2%), four (12.1%), and one (3.0%), respectively, in MDS patients. The frequency of base substitutions was significantly higher than that of the other abnormalities (Po0.05) in MDS patients, but there were no significant differences in the frequencies between base substitutions and the other abnormalities in AA patients. Also, the frequency of insertions was higher in AA patients than in MDS patients (Po0.05), but there were no significant differences in the frequencies of the other various abnormalities between AA and MDS patients. Subsequently, the frequencies of missense mutation, frameshift mutation, inframe deletion, alternative splicing, and nonsense mutation in the PIG-A gene were 24 (49.0%), 23 (46.9%), one (2.0%), 0 (0%), and one (2.0%), respectively, in AA patients and 20 (60.6%), 11 (33.3%), 0 (0%), one (3.0%), and one (3.0%), respectively, in MDS patients. The frequency of missense mutations was significantly higher than that of the other types of PIG-A mutations (Po0.05) in MDS patients, but there were no significant differences in the frequencies between missense mutations and the other abnormalities in AA patients. Moreover, the frequencies of exons 2, 3, 4, 5, and 6 and intron 5 in the PIG-A gene mutations were 28 (57.1%), two (4.1%), six (12.2%), eight (16.3%), five (10.2%), and zero (0%), respectively, in AA patients and 15 (45.5%), three (9.1%), four (12.1%), six (18.2%), four (12.1%), and one (3.0%), respectively, in MDS patients. The frequency of PIG-A mutations in exon 2 was significantly higher than that in the other exons and introns in AA patients (Po0.0001) and MDS patients (Po0.05). Several PIG-A mutations in the GPI-negative granulocytes and/or monocytes were found in all of seven AA patients and eight MDS patients (Tables 2 and 3 ). However, the common PIG-A mutations between CD59 À granulocytes and CD48 À monocytes from each patient, except for Case 5, during the clinical course were not found. Cases 2, 12, and 14 had major PNH clones with a base substitution (T to C) at 1298 bp, a deletion mutation (GT to G) at the 5 0 splicing site in intron 5, and a base substitution (G to T) at 904 bp, respectively (Po0.05 versus the other mutations in GPI-negative cells from these patients) (Tables 2 and 3) , whereas the other PIG-A mutations were minor in both granulocytes and monocytes from the AA and MDS patients examined. In addition, there were different kinds of PIG-A mutations in GPI-negative granulocytes and monocytes from five AA (Cases 1, 2, 3, 4 , and 7) and five MDS patients (Cases 8, 10, 11, 12, and 14) , except for a base substitution at 1045 bp in Case 3 (Table 3 ) and a deletion mutation at the 5' splicing site in intron 5 in Case 12 ( Table 2) .
PIG-A gene analyses for GPI-deficient granulocytes and monocytes from PNH patients
All the PNH patients had PIG-A mutations, including frameshift (54.5%), missense (33.3%), and nonsense (6.1%) mutations and inframe deletions (6.1%), in GPI-negative cells (Table 4 ). The Table 4 PIG-A gene mutations in GPI-negative cells from 11 PNH patients Abbreviations: bp, base pair; A, adenine; G, guanine; T, thymine; C, cytosine; Arg, arginine; Gly, glycine; Cys, cysteine; Tyr, tryptophan; Lys, lysine; Glu, glutamic acid; Ser, serine; Leu, leucine; Ala, alanine; Pro, proline; His, histidine; and Asp, asparaginic acid.
Features of PIG-A mutations in AA and MDS M Okamoto et al
proportions of PIG-A mutations in GPI-negative cells ranged from 20 to 100% (Table 4 ). There were common PIG-A mutations between CD59 À granulocytes and CD48 À monocytes from nine of 11 patients. In addition, five or three of 11 PNH patients had a major clone in CD59 À granulocytes and CD48 À monocytes or either, respectively. Moreover, there were no significant differences in the frequencies of various abnormalities of the PIG-A gene between PNH patients (n ¼ 6) with more than 10% of CD59 À erythrocytes and PNH patients (n ¼ 5) with less than 10% of CD59 À erythrocytes.
Discussion
In this study, we found 49 and 33 different somatic mutations of the PIG-A gene in GPI-negative cells from seven AA and eight MDS patients during the clinical course, respectively, who had less than 1% PNH erythrocytes. Surprisingly, we were not able to find the common PIG-A mutations at intervals in CD59 À granulocytes and CD48 À monocytes from each AA and MDS patient, suggesting that PNH clones with PIG-A mutations, most of which are not major, probably repeat appearance or disappearance at random under the condition of bone marrow failure in AA and MDS. We confirmed that most of the PIG-A mutations in these patients were a deletion, insertion, and substitution of 1 bp, suggesting that deficiencies of GPI-protein expressions in granulocytes and monocytes from AA and MDS patients as well as from PNH patients are due to PIG-A gene abnormalities. Then, we did not identify a hot spot of PIG-A mutations and the specific PIG-A mutation, such as 5-bp deletion as reported in AA/PNH patients by Mortazavi et al. 19 However, the frequencies of PIG-A mutations found in exon 2 were significantly higher than that in the other exons and introns in AA and MDS patients as well as PNH patients (57.6%). This is not surprising because this region encompasses about one half of the whole coding region. Subsequently, we found that the most frequent base abnormalities in the PIG-A gene were base substitutions in AA and MDS patients (Tables 2 and 3) , whereas these were deletions in PNH patients (48.5%) (Table 4) . Moreover, the frequency of missense mutations was significantly higher than that of the other types of PIG-A mutations in MDS patients (Tables 2 and 3) , whereas frameshift mutations were found most frequently in PNH patients (54.5%)(Tables 4). These findings suggest that some characteristics of PIG-A mutations in AA and MDS patients may differ from those of PNH patients with respect to the base abnormalities and types of mutations of the PIG-A gene.
We found that the proportions of PIG-A mutations in GPInegative cells from AA and MDS patients ranged from 5 to 95% (Tables 2 and 3) , implying the existence of PIG-A mutations, other than those found in our study, as Mortazavi et al. 19 also reported even in AA/PNH patients. In addition, we found single or several PIG-A mutations in the GPI-negative granulocytes and/or monocytes from zero (0%) or 15 (100%) of 15 AA and MDS patients and from four (36.4%) or seven (63.6%) of 11 PNH patients, respectively. It has been reported that even GPInegative cells from some healthy individuals had 1-3 PIG-A gene abnormalities, 31 ,32 a finding (Table 3) we too confirmed in the present study. These and our findings suggest that high or low frequencies of several PNH clones in AA and MDS patients or PNH patients, respectively, may indicate the process of selection of a PNH clone among several clones in association with progression of the disorders from AA or MDS to PNH. In fact, the proportions of deletion15 bp mutations in CD59 À granulocytes from Case 5, who transferred AA to PNH at intervals, increased after PNH developed in this patient.
It is not clear how a PNH clone expands in bone marrow. The leading hypothesis seems to be that of Young 4 who considers that PNH clones expand relatively in association with the elimination of GPI-positive hematopoietic precursor cells by cytotoxic T lymphocytes, based on the dual pathogenesis concept presented by Luzzatto and Bessler. 33 It has been reported that GPI-negative cells from PNH patients with several PNH clones consist of one major clone and one or more minor clones, 3, 28, 29 as we also confirmed in the present study (Table 4 ). The frequent existence of several minor PNH clones in most AA and MDS patients in our study suggests that several minor PNH clones may often exist in bone marrow and/or peripheral blood in the presence of pre-PNH, such as AA or MDS. In addition, we found different PIG-A mutations between CD59 À granulocytes and CD48
À monocytes from six AA and three MDS patients during the clinical course, except for a PIG-A mutation from Case 5. These findings suggest that the minor PNH clones in AA and MDS patients are selected or occur heterogeneously during differentiation, maturation, and proliferation of hematopoietic stem cells and progenitor cells of specific blood cell lineages. 3, 28, 29 In contrast, interestingly, we found the common PIG-A mutations, which were not necessarily major, between CD59
À granulocytes and CD48 À monocytes from most PNH patients. Nishimura et al. 34 reported that in PNH patients, the previously predominant PNH clone with a PIG-A gene mutation was present and predominant during the observation period of 6-10 years. This fact and our finding suggest that a predominant PNH clone with a PIG-A mutation may gain clonality with capacity of proliferation or resistance at the level of at least progenitor cells in PNH, expand through immunological mechanisms in bone marrow, and continue to exist for a long period.
In conclusion, our findings indicate that there were some characteristics of PIG-A mutations in AA and MDS patients compared with PNH patients, and that several minor PNH clones in these patients occurred at random during the clinical course. This fact partly explains the transformation of AA or MDS to PNH at intervals.
